Ligand Pharmaceuticals Incorporated LGND 深 滬
已收盤 02-06 16:00:00 美东时间
190.44
-1.250
-0.65%
華盛通- 最 高197.00
- 今 開194.61
- 成交量 27.28万股
- 最 低 189.17
- 昨 收 191.69
- 總市值 37.48亿
- 52周最高 212.49
- 市盈率 靜 --
- 換手率 1.39%
- 52周最低 93.58
- 委 比 -19.76%
- 總股本 1968.17万
- 歷史最高 248.6071
- 量 比 1.63
- 振 幅 4.08%
- 歷史最低 -19.8529
- 每 手 1
- 風險率 37.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
2025-12-11 10:33
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Reported Earlier: Ligand Projects 2026 Revenue Of $245M-$285M, Core Adj. EPS $8.00–$9.002
Ligand will also introduce its 2026 guidance:Total revenue of $245 million to $285 million, comprised of $200 million to $225 million in royalty revenue, $35 million to $40 million in Captisol sales, and $10 million to
2025-12-09 23:55
Reported Earlier: Ligand Reaffirms 2025 Guidance: Sees Core Revenue $225M-$235M, Core Adj. EPS Of $7.40–$7.65
Financial Overview and OutlookToday, Ligand will reiterate its 2025 guidance outlined in November:Total core revenue of $225 million to $235 million comprised of $147 million to $157 million in royalty revenue, $40
2025-12-09 23:55
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
Ligand Pharmaceuticals provided its 2026 financial guidance, anticipating revenue of $245 million to $285 million, a 15% core revenue growth over 2025, with royalty revenue projected at $200 million to $225 million, a 40% increase. The company also expects core adjusted earnings per diluted share of $8.00 to $9.00. Ligand highlighted strong performances in 2025, driven by a 40% increase in royalty revenue and a 30% rise in core adjusted earnings ...
2025-12-09 12:00
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%
Pelthos Therapeutics signed a commercial agreement with a Group Purchasing Organization representing a major Pharmacy Benefit Manager (PBM) in the U.S., enhancing access to ZELSUVMI, the only FDA-approved at-home treatment for molluscum contagiosum, affecting 16.7 million people annually. The partnership, which began on December 1, 2025, aims to expand coverage and distribution, improving patient access, especially for children. ZELSUVMI is a onc...
2025-12-04 12:00
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
2025-11-11 10:49
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
